Applying Guideline Updates and Real-World Experience in CLL: Experts Review State-of-the-Art Evidence and Address Clinical Challenges
The goal of this activity is to improve the knowledge, confidence, and performance of learners to integrate recent findings into the treatment of patients with CLL/SLL.
Provided by the National Comprehensive Cancer Network in partnership with Clinical Care Options, LLC
This program is intended for physicians, physician assistants, nurses, pharmacists, and other healthcare professionals who care for patients with CLL/SLL.
Upon completion of this activity, participants should be able to:
- Design treatment plans for treatment-naive and relapsed/refractory CLL/SLL, including consideration of the agent’s toxicity profile, biomarkers, comorbidities, and patient preference
- Appraise intraclass differences among agents with the similar therapeutic target in CLL/SLL, regarding selectivity, target binding, efficacy, and adverse event profiles
- Develop strategies to address unique clinical challenges and leverage an understanding of the current data and NCCN Guideline to optimize outcomes for patients with CLL/SLL
- Evaluate the evolving role of measurable residual disease, allogeneic hematopoietic cell transplant, and CAR T-cell therapy
William G. Wierda, MD, PhD
Professor of Medicine
Chief, Section of CLL
Department of Leukemia
The University of Texas MD Anderson Cancer Center
Asher Chanan-Khan, MD
Chair, Department of Hematology/Oncology
Brian Hill, MD, PhD
Director, Lymphoid Malignancies Program
Taussig Cancer Institute
NCCN Continuing Education Disclosure Policy
It is the policy of NCCN that all planners, faculty, moderators, authors, reviewers and anyone involved in the planning and delivery of NCCN continuing education activities are expected to disclose all financial relationships they have had in the past 24 months with ineligible companies. The ACCME Standards for Integrity and Independence require that individuals who refuse to provide this information will be disqualified from involvement in the planning and implementation of accredited continuing education presented by NCCN. NCCN identifies, mitigates and discloses to learners all relevant financial relationships.
In addition, all content will be reviewed to ensure education promotes safe, effective patient care and does not promote the products or services of an ineligible company. Content, including any presentation of therapeutic options, will be fair, balanced, evidence-based, scientifically accurate, and free of commercial bias and marketing.
Full disclosure of faculty relationships will be made prior to the activity.
In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
NCCN designates this live activity for a maximum of 2.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
NCCN designates this educational activity for a maximum of 2.5 contact hours.
NCCN designates this application-based continuing education activity for 2.5 contact hours (0.25 CEUs) of continuing education credit. UAN: JA4008196-0000-21-100-L01-P
NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 2.5 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.
- 2.50 AAPA Category 1 CME credit
- 2.50 ACPE contact hours
- 2.50 AMA PRA Category 1 Credit™
- 2.50 ANCC contact hours
- 2.50 Participation